<Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has announced the launch of the generic equivalent to Gleevec (imatinib mesylate) tablets, 100 mg and 400 mg, in the United States for multiple indications approved by the FDA. Gleevec is sold by Novartis as a treatment for a type of blood cancer called chronic myeloid leukemia. RELATED ARTICLES Teva Q2 results boosted by rising Copaxone sales Teva buys Allergan distributor Anda for $500m Teva completes acquisition of Actavis Generics Teva mulls buying Pfizer's Brazilian venture - report Teva said that imatinib mesylate tablets had annual sales of approximately $2.42 billion in the United States, according to IMS data as of May 2016. Separately, it is reported that Teva unit Cephalon has reached a $125 million settlement with 48 US states over its misconduct in preventing the introduction of a generic equivalent of its sleep disorder drug Provigil to the market, following a $1.2 billion settlement with the US Federal Trade Commission. New York Attorney General Eric Schneiderman said on Thursday that Cephalon defrauded the US Patent and Trademark Office in order to secure an additional patent that was later invalidated by a court, and had sued generic drug companies for patent infringement and then settled the suits by paying the companies to delay the launch of generic versions of Provigil. The misconduct took place before Teva acquired Cephalon in 2011. Published by Globes [online], Israel business news - www.globes-online.com - on August 7, 2016 © Copyright of Globes Publisher Itonut (1983) Ltd. 2016
